260 related articles for article (PubMed ID: 18377645)
1. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
[TBL] [Abstract][Full Text] [Related]
2. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
[TBL] [Abstract][Full Text] [Related]
4. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
5. Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.
Yi Y; Loftin L; Wang L; Ratcliffe SJ; Isaacman-Beck J; Collman RG
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):285-92. PubMed ID: 18197116
[TBL] [Abstract][Full Text] [Related]
6. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
7. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
10. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.
Joshi A; Nyakeriga AM; Ravi R; Garg H
J Biol Chem; 2011 Oct; 286(42):36404-13. PubMed ID: 21859712
[TBL] [Abstract][Full Text] [Related]
11. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
[TBL] [Abstract][Full Text] [Related]
12. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
Heredia A; Gilliam B; DeVico A; Le N; Bamba D; Flinko R; Lewis G; Gallo RC; Redfield RR
AIDS; 2007 Jun; 21(10):1317-22. PubMed ID: 17545708
[TBL] [Abstract][Full Text] [Related]
13. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
14. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
15. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of candidate microbicides against cell-associated HIV.
Selhorst P; Grupping K; Bourlet T; Delézay O; Ariën KK; Vanham G
Antimicrob Agents Chemother; 2012 Feb; 56(2):805-15. PubMed ID: 22083472
[TBL] [Abstract][Full Text] [Related]
17. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.
Toma J; Whitcomb JM; Petropoulos CJ; Huang W
AIDS; 2010 Sep; 24(14):2181-6. PubMed ID: 20639728
[TBL] [Abstract][Full Text] [Related]
18. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
19. Baseline susceptibility of primary HIV-2 to entry inhibitors.
Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
